VANI
NASDAQVivani Medical Inc.
Price$1.17+0.01 (+1.30%)
2026-03-052026-06-08
News · 26 weeks26-40%
2025-12-142026-06-07
Mix1390d
- SEC Filings7(54%)
- Insider3(23%)
- Other2(15%)
- Offering1(8%)
Latest news
25 items- SECVivani Medical Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Vivani Medical, Inc. (0001266806) (Filer)
- PRVivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026ALAMEDA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and host investor and partner meetings at the Jefferies Global Healthcare Conference taking place June 2-4, 2026 in New York, New York. Details of Dr. Mendelsohn's presentation are as follows: Date: Thursday, June 4, 2026Time: 11:05 a.m. - 11:35 a.m. Eastern Time Location: New York Marriott Marquis, 1535 Broadway Following the presentation, a replay will be available for 90 days on the Investors sec
- INSIDERDirector Williams Gregg bought $1,999,999 worth of shares (1,587,301 units at $1.26) (SEC Form 4)4 - Vivani Medical, Inc. (0001266806) (Issuer)
- SECVivani Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Vivani Medical, Inc. (0001266806) (Filer)
- SECSEC Form 10-Q filed by Vivani Medical Inc.10-Q - Vivani Medical, Inc. (0001266806) (Filer)
- PRVivani Medical Reports First Quarter 2026 Financial Results and Provides Business UpdateInitiation of SLIM-1™ clinical trial, a Phase 1 study of NPM-139, a semaglutide implant under development for chronic weight management, on track for mid-year 2026 $28 million in cash, cash equivalents, restricted cash and capital commitments expected to fund current operating plan through the first half of 2027 ALAMEDA, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting subdermal drug implants utilizing its proprietary NanoPortal™ technology, today reported financial results for the first quarter ended March 31, 2026, and provided a business update. V
- SECSEC Form DEFA14A filed by Vivani Medical Inc.DEFA14A - Vivani Medical, Inc. (0001266806) (Filer)
- SECSEC Form DEF 14A filed by Vivani Medical Inc.DEF 14A - Vivani Medical, Inc. (0001266806) (Filer)
- INSIDERSEC Form 4 filed by Williams Gregg4 - Vivani Medical, Inc. (0001266806) (Issuer)
- SECVivani Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Vivani Medical, Inc. (0001266806) (Filer)
- SECSEC Form 10-K filed by Vivani Medical Inc.10-K - Vivani Medical, Inc. (0001266806) (Filer)
- PRVivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateSuccessful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under development for chronic weight management toward a Phase 1 clinical study with results anticipated by the end of 2026. Single preclinical administration of semaglutide implant configuration demonstrates continued semaglutide exposure and >20% sham-adjusted weight loss for a full year. Solid cash position from multiple recent financings will support operations into mid-2027 and enable the projected completion of key milestones including the Phase 1 study of NPM-139. ALAMEDA, Calif., March 26
- INSIDERDirector Williams Gregg bought $1,683,335 worth of shares (1,575,231 units at $1.07) (SEC Form 4)4 - Vivani Medical, Inc. (0001266806) (Issuer)
- INSIDERDirector Williams Gregg bought $1,983,333 worth of shares (1,866,492 units at $1.06) (SEC Form 4)4 - Vivani Medical, Inc. (0001266806) (Issuer)
- PRVivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology Cortigent is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind The Company is also developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysis due to stroke ALAMEDA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that Cortigent, Inc. ("Cortigent"), its wholly-owned subsidiary developing brain implant de
- INSIDERDirector Williams Gregg bought $1,999,999 worth of shares (1,351,351 units at $1.48) (SEC Form 4)4 - Vivani Medical, Inc. (0001266806) (Issuer)
- SECVivani Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Vivani Medical, Inc. (0001266806) (Filer)
- PRVivani Medical, Inc. Announces Closing of Common Stock OfferingALAMEDA, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the closing of its previously announced best efforts registered direct offering of 1,689,200 shares of its common stock at an offering price of $1.48 per share and a concurrent private placement of 1,351,351 shares of its common stock at an offering price of $1.48 per share purchased by Gregg Williams, the Chairman of the Company's board of directors. Gross proceeds from the two transactions were approximately $4.5 million, before deducting fees and offering expens
- SECSEC Form 424B5 filed by Vivani Medical Inc.424B5 - Vivani Medical, Inc. (0001266806) (Filer)
- PRVivani Medical, Inc. Announces Pricing of Common Stock OfferingALAMEDA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the pricing of a best efforts registered direct offering of 1,689,200 shares of its common stock at an offering price of $1.48 per share and concurrent private placement of 1,351,351 shares of its common stock at an offering price of $1.48 per share purchased by Gregg Williams, the Chairman of the Company's board of directors. The registered offering and the private placement were priced "at-the-market" under the rules and regulations of The Nasdaq Stock Market LLC
- PRVivani Subsidiary Cortigent to Present Orion System's Advanced Brain Implant Technology in Poster Session at NANS 2026Cortigent is a leading developer of brain interface devices based on precision neurostimulation technology The company's new Orion cortical stimulation system for visual perception, designed to treat most common forms of blindness, successfully completed a six-year Early Feasibility Study Cortigent is also developing a new medical device aimed at improving the recovery of arm and hand motion in patients suffering from paralysis due to stroke ALAMEDA, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that its wholly-own
- INSIDERDirector Williams Gregg bought $1,983,334 worth of shares (1,737,765 units at $1.14) (SEC Form 4)4 - Vivani Medical, Inc. (0001266806) (Issuer)
- INSIDERSEC Form 4 filed by Director Bradbury Daniel4 - Vivani Medical, Inc. (0001266806) (Issuer)
- INSIDERSEC Form 4 filed by Director Williams Gregg4 - Vivani Medical, Inc. (0001266806) (Issuer)
- INSIDERDirector Mendelsohn Aaron gifted 20,000 shares and bought $24,600 worth of shares (20,000 units at $1.23) (SEC Form 4)4 - Vivani Medical, Inc. (0001266806) (Issuer)
VANI FAQ
5 questionsWhere does VANI stock trade?
Vivani Medical Inc. (VANI) is listed on NASDAQ.What sector and industry is VANI in?
Vivani Medical Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.When did Vivani Medical Inc. go public?
Vivani Medical Inc. (VANI) completed its IPO in 2014.What companies are similar to VANI?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare VANI side-by-side with any of them on Quantisnow.How can I track VANI on Quantisnow?
Quantisnow aggregates Vivani Medical Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VANI to receive live email and push alerts on every new disclosure.